'established', 'glyph' => '✓', 'label' => 'Established', 'description' => 'Strong RCT evidence; widely prescribed or validated.', ), array( 'state' => 'promising', 'glyph' => '◐', 'label' => 'Promising', 'description' => 'Meaningful human data accumulating; not yet RCT-strong.', ), array( 'state' => 'investigational', 'glyph' => '?', 'label' => 'Investigational', 'description' => 'Mechanism plausible; human trials sparse.', ), array( 'state' => 'insufficient', 'glyph' => '⊘', 'label' => 'Insufficient Evidence', 'description' => 'Not enough data to say anything responsible.', ), array( 'state' => 'cautionary', 'glyph' => '⚠', 'label' => 'Cautionary', 'description' => 'Active safety signals or misuse patterns.', ), ); /** * Featured monograph post IDs. These are the three exemplar monographs * loaded during brand sprint v2.0.0 (2026-04-26). * Semaglutide=211 (established), BPC-157=36 (investigational), Melanotan-II=177 (cautionary). */ $featured_monograph_ids = array( 211, 36, 177 ); ?>

1 ) { $last_word = array_pop( $words ); echo esc_html( implode( ' ', $words ) ) . ' ' . esc_html( $last_word ) . ''; } else { echo esc_html( $hero_title ); } ?>

$featured_monograph_ids, 'post_type' => 'peptide', 'posts_per_page' => 3, 'orderby' => 'post__in', 'post_status' => 'publish', ) ); if ( ! empty( $featured_posts ) ) : ?>